CASI Pharmaceuticals CASIF
OTC CASIF
$0.12 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

CASI Pharmaceuticals (CASIF) Other Accumulated Expenses (2021 - 2025)

Updated

CASI Pharmaceuticals' Other Accumulated Expenses came in at $11.82 million for Q4 2025, unchanged from $11.82 million a year earlier.

Analysis

CASI Pharmaceuticals (CASIF) Other Accumulated Expenses (2021 - 2025) Analysis & Trends

Going back to Q4 2021, CASI Pharmaceuticals' Other Accumulated Expenses data covers 5 quarters.

  • Other Accumulated Expenses carries a four-year compound annual growth rate of -2.8% (FY2021 to FY2025).
  • Going back by year, Other Accumulated Expenses was $11.82 million in FY2024 (-46.3%), $22 million in FY2023 (+86.1%), $11.82 million in FY2022 (-10.6%) and $13.22 million in FY2021.
  • The five-year range for quarterly Other Accumulated Expenses is $11.82 million (Q4 2022) to $22 million (Q4 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 CASI Pharmaceuticals 2.47 Mn -18.36 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 11.82 Mn
Dec 31, 2024 11.82 Mn
Dec 31, 2023 22.00 Mn
Dec 31, 2022 11.82 Mn
Dec 31, 2021 13.22 Mn
API Access

CASI Pharmaceuticals Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=CASIF&period=max&api_key=YOUR_API_KEY